Ignite Creation Date:
2024-05-06 @ 8:43 AM
Last Modification Date:
2024-10-26 @ 12:04 PM
Study NCT ID:
NCT02804646
Status:
UNKNOWN
Last Update Posted:
2016-06-21
First Post:
2016-06-15
Brief Title:
Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
Sponsor:
Anhui Provincial Hospital
Organization:
Anhui Provincial Hospital
Study Overview
Official Title:
Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative
Status:
UNKNOWN
Status Verified Date:
2016-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to discuss the efficacy and safety of recombinant human endostatinendostar durative intravenous transfusion combined with pemetrexed plus cisplatin or carboplatin in the first-line treatment of advanced lung adenocarcinoma with wild-type EGFR or ALK-negativecompared with chemotherapy without endostar
Detailed Description:
With the progress of molecular biology and translational medical research the treatment of advanced non-small cell lung cancer goes into the era of personalized medicine Lung adenocarcinoma accounts for about 50 of non-small cell lung cancerIn recent years although individualized targeted therapy in lung adenocarcinoma progress by leaps and bounds but the research of wild-type EGFR or ALK-negative lung adenocarcinoma is extremely lag lack of clinically effective targeted drugsAs time goes onalmost all of the EGFR-TKI treatment of lung adenocarcinoma will be resistant one dayand patients need other treatments such as chemotherapyCurrently chemotherapy is still the main treatment for advanced lung adenocarcinoma with EGFR wild-type and unkownMany researches has reported thatendostar combined with chemotherapy in patients with advanced NSCLC can significantly improve the patients RRTTP and did not increase the adverse effects of chemotherapyRecentlyendostar durative intravenous transfusion has been widely accept and use because of the lower toxicityThe purpose of our study was to discuss the efficacy and safety of endostard durative intravenous transfusion combined with chemotherapyIn our studyPatients with ⅢbⅣ lung adenocarcinoma were divided into two groups randomlyone group was treated with endostar durative intravenous transfusion combined with chemotherapywhile the other group with chemotherapy pemetrexed plus cisplatin or carboplatin onlyIn the endPFSORRDCR and OS were compared between these two groups
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None